Klotho Neurosciences, INC

Greenland Mines Ltd. has adopted a limited-duration stockholder rights plan to protect shareholder value and ensure fair treatment in potential acquisition scenarios.

Greenland Mines Ltd. announced the adjournment of its special meeting of stockholders to August 7, 2026, following the approval of an adjournment proposal.

Greenland Mines Ltd. announced a significant upgrade to its Skaergaard precious and critical metals project, with a new S-K 1300-compliant report showing a 31% increase in indicated PdEq ounces and a 36% grade uplift.

Greenland Mines Ltd. announced the termination of its At-the-Market Sales Agreement with A.G.P./Alliance Global Partners, effective July 4, 2026.

Greenland Mines Ltd. has dismissed BCRG Group as its independent auditor and appointed Simon & Edward LLP, effective June 23, 2026.

Greenland Mines Ltd. has successfully closed a private placement of 15,000,000 shares of common stock, raising approximately $3.75 million in gross proceeds.

Greenland Mines Ltd. reports a strategic pivot to mining following the acquisition of the Skaergaard Project, while maintaining biotech operations and addressing going concern risks.

Klotho Neurosciences, Inc. reported a significant net loss for Q3 2025 and the nine months ended September 30, 2025, while substantially increasing cash reserves through financing activities, but faces a 'going concern' warning and Nasdaq compliance issues.

Klotho Neurosciences, a pre-revenue biotech, reported significantly increased losses for Q2 2025 but bolstered its cash position through recent capital raises and achieved Orphan Drug Designation for its ALS gene therapy.

Klotho Neurosciences' Q1 2025 results reveal a widened net loss and highlight substantial doubt about the company's ability to continue as a going concern without additional funding.

Klotho Neurosciences, Inc. reports a significant increase in net loss for the third quarter of 2024, primarily due to increased share-based compensation and expenses related to its recent business combination.

Anew Medical, Inc. reports its financial results for the quarter ended June 30, 2024, following its recent merger, highlighting increased operating expenses and a net loss, while also detailing its current assets, liabilities, and ongoing development of its licensed platforms.

Greenland Mines Ltd, formerly Klotho Neurosciences, Inc., is shifting its strategic focus to critical minerals mining following a recent acquisition, despite reporting significantly increased net losses and substantial doubt about its ability to continue as a going concern for 2025.

Klotho Neurosciences enters into a securities purchase agreement for \$2.17 million via senior convertible notes and warrants to fund general corporate purposes.

Redwoods Acquisition Corp. has extended the deadline for its merger with ANEW Medical, while also reporting its financial results for the year ended December 31, 2023.

Jason David Sawyer, a Director of Klotho Neurosciences, Inc., purchased 240,000 shares of common stock on July 22, 2026 for $0.23 per share.

Jon Mcgarity, a Director of Klotho Neurosciences, Inc., purchased 140,000 shares of common stock on July 20, 2026 for $0.18 per share.

Jeff Leblanc, Chief Financial Officer of Klotho Neurosciences, Inc., purchased 1,400,000 shares of common stock on July 16, 2026 for $0.18 per share.

Klotho Neurosciences' Chief Financial Officer, Jeff LeBlanc, acquired 2.5 million shares of common stock through an equity incentive plan grant.

Klotho Neurosciences Director Riad El-Dada acquired 350,000 shares of common stock through an equity incentive plan grant.

Klotho Neurosciences Director Samuel M. Zentman acquired 350,000 shares of common stock through an equity incentive plan, increasing his direct beneficial ownership to 1,086,440 shares.

Greenland Mines Ltd. is holding a special meeting on June 18, 2026, to seek shareholder approval for one or more reverse stock splits to regain compliance with Nasdaq's minimum bid price requirement.

Klotho Neurosciences, Inc. will hold a Special Meeting to vote on a reverse stock split to meet Nasdaq listing requirements and an increase in shares for its equity incentive plan.

Klotho Neurosciences, Inc. will hold a Special Meeting to vote on a reverse stock split to meet Nasdaq listing requirements and an increase in its equity incentive plan to attract and retain talent.

Klotho Neurosciences is asking stockholders to approve a reverse stock split to meet Nasdaq's minimum bid price requirement and attract institutional investors.

Klotho Neurosciences, Inc. filed an S-1 registration statement for the resale of up to 35 million shares of common stock by existing selling stockholders, including shares convertible from Series C Preferred Stock.

Klotho Neurosciences is registering for resale up to 43.7 million shares of common stock, including shares issuable upon conversion of notes and exercise of warrants, by existing shareholders.

ANEW Medical, Inc. files an amendment to its S-1 registration statement primarily to include a revised exhibit related to auditor consent.

ANEW Medical is registering for resale up to 21.5 million shares of its common stock, including shares issuable upon warrant exercises and shares held by selling stockholders.

Strategic EP, LLC and Alexander Chase Deitch have jointly reported a 5.5% beneficial ownership stake in Greenland Mines Ltd, totaling 6,687,472 common shares.

Austria Capital LLC has reported a beneficial ownership of 4.99% of Klotho Neurosciences Inc.'s common stock, totaling 1,621,470 shares, indicating a passive investment strategy.

Austria Capital LLC has disclosed a 9.405% beneficial ownership stake in Klotho Neurosciences Inc., holding 2,000,000 shares of common stock.